Forest Laboratories and Almirall have submitted a new drug application to the FDA for their inhaled aclidinium bromide, a dry powder long-acting inhaled antimuscarinic agent for the treatment of COPD. Forest has licensed the US rights to the product; Almirall retains the rights elsewhere.
The aclidinium bromide formulation is delivered via a multi-dose DPI and will be sold under the name Eklira.
Read the Forest and Almirall press release.
